INTRODUCTION TO CLINICAL PRACTICE: AN IMPORTANT CONTRIBUTION OF GENERAL MEDICINE TO MEDICAL EDUCATION

Year 2001, Volume: 14 Issue: 4, 255 - 258, 03.12.2016

Çağrı Kalaca Ahmet Arzık Sibel Kalaca Pemra Ünalan

Abstract

Alzheimer’s Disease (AD) is a progressive disease involving the loss of several cognitive functions. In the etiology there are mutation deficits in some genes and resultant mutational changes in amyloid precursor protein, presenilin 1 and 2, apolipoprotein E and low-density- lipoprotein-bound receptor protein (1).

References

• Victor M, Ropper AH. Degenerative diseases of the nervous system. In: Adam's and Victor's Principles of neurology. 7th ed. USA: McGrawHill, 2001:1114-1116.
• Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer's disease. Drugs 2001:61;41-52.
• Kaplan H, Sadock B. Dementia. In: Kaplan and Sadock's Synopsis of Psychiatry. Middle East ed., 8th ed. Giza - Egypt: Wiliams & Wilkins, ¡998:328-345.
• World Health Organization. The ICD-IO Classification of Mental and Behavioural Disorders. World Health Organization, Genova, 1992,
• Delirium, dementia, and amnestic and other cognitive disorders. In: The Task Force on DSM-IV and other committees and work groups of manual of mental disorders: DSM- IV. 4th ed. American Psychiatric Association, Washington, DC, 1994:123-163.
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the ITinCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease, neurology 1984:34; 939-944.
• Kumral E, Acarer A. Alzheimer hastalığında tanı kriterleri ve genel klinik özellikler. İn: Alzheimer Hastalığı, Kutay FZ, ed. İzmir: Ege University Press, 2000:1-18.
• Çağrı Yalgın, et al
• Zurad EG. new treatments of Alzheimer disease: a review. Drug Benefit Trends 2001: 13:27-40.
• Terry RD, Masliah E, Hansen LA. Structural basis of the cognitive alteration in Alzheimer's disease. In: Terry RD, Ratzman R, Bick RL, eds. Alzheimer Disease. Raven Press, Hew York, 1994:179-196.
• Ratzman R. Alzheimer's disease, n Eng J Pled 1986:363:964-973.
• Rozemuiier JM. neuropathology of dementias.
• Syllabus 2001, The Amsterdam International Medical Summer School, "Bridging neurology 8c Psychiatry: Dementia, Depression,
• Schizophrenia and Addiction". July 15-28, 2001, Amsterdam, the netherlands.
• Sezer C, Mem iş L. Alzheimer hastalığı histopatolojisi. Demans Dergisi 2001:1:42-49.
• Rutay FZ. Alzheimer hastalığının
• etyopatogenezindeki biyokimyasal
• mekanizmalar. In: Alzheimer Hastalığı, Rutay FZ, ed. İzmir: Ege University Press, 2000:19- 51.
• Lewis J, Dickson DW, Lin WL et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001:293:1487-1491.
• Götz J, Chen F, van Dorpe J, Tiitsch RM. Formation of neurofibrillay tangles in P301L tau transgenic mice induced by Ap42 fibrils. Science 2001 -.293; 1491-1495.
• McGieenon BM, Dynan RB, Passmore AP. Acetylcholinesterase inhibitors in Alzheimer's disease. Br J Clin Pharmacol 1999:48:471- 480.
• Benzi G, Moretti A. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? Eur J Pharmacol 1998:346; 1-13.
• Guillozet AL, Smiley JF, Mash DC, et al. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Heurol 1997:42:909- 918.
• Wright Cl, Geula C, Mesulam MM. neurological cholinesterases in the normal brain and Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Heurol 1993:34;3 73-384.
• Rosen WG, Mohs RC, Davis RL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984:141,1356-1364.
• Berg L, Miller JP, Baty J, et al. Mild senide dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Heurol 1992:31 ;242- 249.
• Madden S, Spaldin V, Park BR. Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 1995:28:449-45 7.
• Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 1992:268:2523-2529.
• Rnapp MJ, Rnopman DS, Soloman PR, et al. A 30-week randomized controlled trial of lilgh- dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994:271:985-991.
• Farlow MR, Lahiri DR, Poirier J, et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Heurology 1998:50:669-677.
• Rogers SL, Fried ho ff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCI following single oral doses. Br J Clin Pharmacol 1998:46 Suppl I: 1-6.
• The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind placebo-controlled trial. The Donepezil Study Group. Dementia 1996:7:293-303.
• Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Heurology 1998:50; 136-145.
• Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of EHA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. The EHA 713 B352 Study Group. Int J Geriatr Psychopharmacol 1998:1 ;55-65.
• Rosier M, Anand R, Cicin-Sain A, et al. Efficacy
• and safety of rivastigmine in patients with Alzheimer's disease: international
• randomised controlled trial. Br Med J 1999: 318:633-640.
• Raskind MA, Peskind ER, Wessel T. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Heurology 2000:54:2261 -2268.
• Tariot PH, Solomon PR, Morris JC, et al. A 5- month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA- 10 Study Group. Heurology 2000:54:2269- 2276.